reviewTop 1% cited

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

Journal of the American Academy of Dermatology · 2019 · Vol. 80(4) · pp. 1029–1072

Alan Menter✉(Baylor Medical Center at Garland)Bruce Strober(University of Connecticut)Daniel H. Kaplan(University of Pittsburgh)Darío Kivelevitch(Baylor Medical Center at Garland)Elizabeth Farley Prater(University of Oklahoma Health Sciences Center)Benjamin K. Stoff(Emory University)April W. Armstrong(University of Southern California)Cody Connor(University of Alabama at Birmingham)Kelly M. Cordoro(University of California, San Francisco)Dawn Marie R. Davis(Mayo Clinic)Boni E. Elewski(University of Alabama at Birmingham)Joel M. Gelfand(University of Pennsylvania)Kenneth B. Gordon(Medical College of Wisconsin)Alice B. Gottlieb(Icahn School of Medicine at Mount Sinai)Arthur Kavanaugh(University of California, San Diego)Matthew Kiselica(National Psoriasis Foundation)Neil J. Korman(University Hospitals of Cleveland)Daniela Kroshinsky(Massachusetts General Hospital)Mark Lebwohl(Icahn School of Medicine at Mount Sinai)Craig L. Leonardi(Central Dermatology)Jason Lichten(ASIS Foundation)Henry W. Lim(Henry Ford Hospital)Nehal N. Mehta(National Heart Lung and Blood Institute)Amy S. Paller(Northwestern University)Sylvia L. ParraArun L. Pathy(Colorado Permanente Medical Group)Reena Rupani(Central Dermatology)Michael Siegel(ASIS Foundation)Emily Wong(Joint Base San Antonio)Jashin J. Wu(Dermatology Research and Education Foundation)Vidhya Hariharan(American Academy of Dermatology)Craig A. Elmets(University of Alabama at Birmingham)

View via DOI Publisher page

Psoriasis: Treatment and Pathogenesis Health Systems, Economic Evaluations, Quality of Life Dermatology and Skin DiseasesMedicinePsoriasisDermatologyJoint (building)MEDLINEIntensive care medicine

MeSH terms

Certolizumab PegolEtanerceptAdalimumabInfliximabUstekinumabAntibodies, MonoclonalBiological ProductsDermatologic AgentsDrug Therapy, CombinationHumansPiperidinesPsoriasisPyrimidinesPyrrolesEvidence-Based Medicine

Citations

880

FWCI

38.30

field-weighted impact

References

341

Percentile

100%

vs. same field & year

Citations per year

References